Sivry Rance

Researchers are evaluating orforglipron to measure its effects on cardiovascular outcomes in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This phase 3 study aims to compare orforglipron with a placebo to better understand its impact on major cardiovascular events over about five years. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally along with standard care. The study is double-blinded, meaning neither participants nor researchers will know who receives the active drug or placebo during the trial period. During the study, participants will be followed for around five years, with researchers monitoring the time to the first major cardiovascular event and additional outcomes such as cardiovascular and kidney events, changes in kidney function measured by eGFR, and the onset of type 2 diabetes. The study includes regular assessments to track these outcomes and ensure participant safety throughout the long-term follow-up.

This trial focuses on comatose adult patients after cardiac arrest who show electrographic status epilepticus ESE on continuous EEG. It aims to evaluate whether treating ESE with anti-seizure medications improves patient outcomes and to examine the impact of such treatment on healthcare costs. The study responds to the uncertainty about whether ESE treatment benefits patients or if ESE reflects irreversible brain damage, which affects treatment decisions and resource use in intensive care. Participants are randomly assigned to one of two groups the intervention group receives standard care plus a stepwise anti-seizure treatment following protocols for status epilepticus, while the control group receives standard care without anti-seizure treatment. The anti-seizure treatment involves up to three steps with medications including benzodiazepines, anti-seizure drugs like levetiracetam, valproate, or lacosamide, and continuous sedative agents such as midazolam, propofol, or ketamine. Each step is applied promptly if the previous step does not control ESE. Participants will be monitored with continuous EEG as part of standard care, and their functional recovery will be assessed using the extended Glasgow Outcome Scale eGOS six months after cardiac arrest. Additional evaluations include quality of life, cognitive function, and healthcare resource use, with cost-effectiveness analyzed separately for Belgium and the Netherlands. The study is conducted openly with blinded endpoint assessment across multiple intensive care units, with a participation period extending up to six months or longer for outcome measurements.